Copyright ©The Author(s) 2015.
World J Hepatol. Mar 27, 2015; 7(3): 593-599
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.593
Table 1 Clinical trials of chemoprevention effects in hepatocarcinogenesis
TherapyRef.YearStudy designTreated patients/controlDiseaseCombinedmedicationHepatocarcinogenesis rate
PhlebotomyKato et al[16]2007Open labeled35/40Chronic hepatitis CNoneHepatocarcinogenesis rates in iron depletion and control were 5.7% and 17.5% at the end of the fifth year, and 8.6% and 39% in the tenth year, respectively (P = 0.018)
GlycyrrhizinIkeda[29]2007Case-control244/102Chronic hepatitis CNoneCrude carcinogenesis rates in the treated and untreated group were 13.3%, 26.0% at the fifth year, and 21.5% and 35.5% at the 10th year, respectively (P = 0.021)
GlycyrrhizinArase et al[32]1997Case-control84/109Chronic hepatitis CNoneThe 10th-year rates of cumulative HCC incidence for the treated and untreated group were 7% and 12%, and the 15th-yr rates were 12% and 25%, respectively (P = 0.032)
Ursodeoxycholic AcidTarao et al[44]2005Case-control56/46Hepatitis C virus -associated liver cirrhosisSho-saiko-to, Ursodeoxycholic acidThe cumulative 5-yr incidence of HCC in the patients treated with UDCA was 17.9% and was significantly lower than that in patients not treated with UDCA (39.1%; P = 0.025)
Vitamin EKakizaki et al[48]2001Randomized controlled44/39Chronic hepatitis CNoneCumulative tumor-free survival tended to be higher in the Vit E group than in controls, albeit statistically insignificant
Sho-saiko-toOka et al[64]1995Randomized open controlled130/130Cirrhosis from chronic liver diseaseNoneThe cumulative incidence curve for 5 yr of the trial group was lower than that of the control group (P = 0.071), albeit statistically insignificant